Argus raises Regeneron stock price target on Dupixent strength
Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.
How this was made
The 30-second read
Why it matters
The combined regulatory and analyst actions create a fresh bullish catalyst for REGN.
Market read
Regeneron's stock is likely to rally on the day of the FDA approval and analyst upgrades.
What to watch
Potential pricing pressure from competing therapies and reimbursement uncertainties.
Background
Regeneron reported strong Q3 sales driven by Dupixent and announced FDA approval for Livsayis, while analysts raised price targets.
Ticker impact
Argus raised its price target to $1,050 and FDA approved Regeneron's Livsayis, indicating fresh positive catalyst.
likely upward pressure as the market prices in the approval and upgraded targets
New regulatory approval and multiple analyst upgrades provide fresh, material information that can move the stock immediately.
Market effects
Biopharma sector may see broader optimism for antibody therapeutics after the approval.
US biotech indices could gain modestly.
Limited to investors tracking US-listed biotech stocks.
Counterpoint
If the approval faces post-market safety concerns, the rally could be short-lived.
Key entities
- companyRegeneron Pharmaceuticals
US-listed biopharma developing antibody therapies.
- analystArgus Research
Equity research firm that raised REGN price target.





